Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 9, 2004, Pages 546-550

  Xiao, Yong Sheng ^a   Tang, Zhao You ^a   Fan, Jia ^a   Zhou, Jian ^a   Wu, Zhi Quan ^a   Sun, Qi Man ^a   Xue, Qiong ^a   Zhao, Yan ^a   Liu, Yin Kun ^a   Ye, Sheng Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Capecitabine; Chemotherapy; Hepatocellular carcinoma; Interferon alpha; Thymidine phosphorylase

Indexed keywords

ALPHA2A INTERFERON; CAPECITABINE; THYMIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VOLUME; UPREGULATION;

EID: 4344593370     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0565-8     Document Type: Article

References (24)

1. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493
2. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast cancer. Cancer 92:1759-1768
3. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H (1993) Cytokines in duce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32:333-338
4. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine of 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127-134
5. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y (1992) Angiogenic factor. Nature (Lond) 356:668
6. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (Lond) 338:557-562
7. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorourcil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 155:1091-1097
8. Ishitsuka H (2000) Capecitabine: preclinical pharmacology studies. Invest New Drugs 18:343-354
9. Li G, Kawakami S, Kageyama Y, Yan C, Saito K, Kihara K (2002) IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5′-deoxy-5-fluorouridine in bladder cancer cells. Anticancer Res 22:2607-2612
10. Meropol NJ (1998) Oral fluoropyrimidine in the treatment of colorectal cancer. Eur J Cancer 34:1509-1513
11. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and caner tissue. Eur J Cancer 34:1274-1281
12. Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, Kirchner H, Atzpodien J (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83:583-587
13. Okuda K (1980) Primary liver cancers in Japan. Cancer 45:2663-2672
14. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153-156
15. Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito R (1998) The oral fluorouracil prodrugs. Oncology 12:48-51
16. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/ Taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019
17. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297
18. Schwartz EL, Wan E, Wang FS, Baptiste N (1998) Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 58:1551-1557
19. Sun FX, Tang ZY, Liu KD, YeS, Xue Q, Gao DM, Ma ZC (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239-243
20. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A:1227-1232
21. Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 17:1915-1925
22. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL (2000) High-dose and long-term therapy with interferon-alfha inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43-48
23. Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL (2000) Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57-61
24. Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Xiao YS, Shi YH, Li XM, Sun QM, Liu YK, Ye SL (2003) Capecitabine inhibits post-operative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of PD-ECGF. Clin Cancer Res (accepted)